Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

CONTEXT The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends myeloablative allogeneic stem cell transplantation (SCT) for poor-risk but not for good-risk AML. Allogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent benefit for intermediate-risk AML. OBJECTIVE To quantify relapse-free survival (RFS) and overall survival benefit of allogeneic SCT for AML in CR1 overall and also for good-, intermediate-, and poor-risk AML. METHODS Systematic review and meta-analysis of prospective trials evaluating allogeneic SCT vs nonallogeneic SCT therapies for AML in CR1. The search used the combined search terms allogeneic; acut* and leukem*/leukaem*/leucem*/leucaem*/aml; myelo* or nonlympho* in the PubMed, Embase, and Cochrane Registry of Controlled Trials databases in March 2009. The search identified 1712 articles. STUDY SELECTION Prospective trials assigning adult patients with AML in CR1 to undergo allogeneic SCT vs nonallogeneic SCT treatment(s) based on donor availability and trials reporting RFS and/or overall survival outcomes on an intention-to-treat, donor vs no-donor basis were identified. DATA EXTRACTION Two reviewers independently extracted study characteristics, interventions, and outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were determined. DATA SYNTHESIS Overall, 24 trials and 6007 patients were analyzed (5951 patients in RFS analyses and 5606 patients in overall survival analyses); 3638 patients were analyzed by cytogenetic risk (547, 2499, and 592 with good-, intermediate-, and poor-risk AML, respectively). Interstudy heterogeneity was not significant. Fixed-effects meta-analysis was performed. Compared with nonallogeneic SCT, the HR of relapse or death with allogeneic SCT for AML in CR1 was 0.80 (95% CI, 0.74-0.86). Significant RFS benefit of allogeneic SCT was documented for poor-risk (HR, 0.69; 95% CI, 0.57-0.84) and intermediate-risk AML (HR, 0.76; 95% CI, 0.68-0.85) but not for good-risk AML (HR, 1.06; 95% CI, 0.80-1.42). The HR of death with allogeneic SCT for AML in CR1 was 0.90 (95% CI, 0.82-0.97). Significant overall survival benefit with allogeneic SCT was documented for poor-risk (HR, 0.73; 95% CI, 0.59-0.90) and intermediate-risk AML (HR, 0.83; 95% CI, 0.74-0.93) but not for good-risk AML (HR, 1.07; 95% CI, 0.83-1.38). CONCLUSION Compared with nonallogeneic SCT therapies, allogeneic SCT has significant RFS and overall survival benefit for intermediate- and poor-risk AML but not for good-risk AML in first complete remission.

[1]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[2]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[3]  H. Dombret,et al.  A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup , 2002 .

[4]  M. O’connell,et al.  Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group. , 1992, Leukemia.

[5]  P. Hurteloup,et al.  Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). , 1997, Blood.

[6]  X. Thomas,et al.  Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Nimer,et al.  Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Piccaluga,et al.  Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine , 2006, Leukemia & lymphoma.

[9]  I. Olkin,et al.  Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement , 2000, Oncology Research and Treatment.

[10]  S Greenland,et al.  Invited commentary: a critical look at some popular meta-analytic methods. , 1994, American journal of epidemiology.

[11]  M. Egger,et al.  The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.

[12]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .

[13]  I Olkin,et al.  Re: "A critical look at some popular meta-analytic methods". , 1994, American journal of epidemiology.

[14]  E. Montserrat,et al.  Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Awan,et al.  Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  D. Niederwieser,et al.  Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission , 2009, Leukemia.

[17]  F. Appelbaum,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  Augustin Ferrant,et al.  Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? , 2007, Blood.

[19]  David Moher,et al.  Meta-analysis of Observational Studies in Epidemiology , 2000 .

[20]  R. Hills,et al.  Long-term results of the MRC AML10 trial. , 2006, Clinical advances in hematology & oncology : H&O.

[21]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[22]  J. Esteve,et al.  Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. , 2004, Haematologica.

[23]  D M Eddy,et al.  Synthesis of environmental evidence: nitrogen dioxide epidemiology studies. , 1992, Journal of the Air & Waste Management Association.

[24]  R. Gray,et al.  How to avoid bias when comparing bone marrow transplantation with chemotherapy. , 1991, Bone marrow transplantation.

[25]  J. Bourhis,et al.  Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.

[26]  P. Nathan,et al.  Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. , 2004, Journal of the National Cancer Institute.

[27]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[28]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[29]  J. Downing,et al.  Acute myeloid leukemia. , 1999, The New England journal of medicine.

[30]  Hartmut Döhner,et al.  Acute myeloid leukaemia , 2006, The Lancet.

[31]  I. Grotto,et al.  Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. , 2004, Leukemia research.

[32]  H. Dombret,et al.  Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.

[33]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[34]  Zhong Li-ye,et al.  Early Allogeneic Stem-Cell Transplantation for Young Adults with Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience , 2007 .

[35]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[36]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[37]  M. Caligiuri,et al.  MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[38]  M. Sorror,et al.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. , 2007, Blood.

[39]  F. Mandelli,et al.  The influence of HLA‐matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA , 1998, British journal of haematology.

[40]  K. Döhner,et al.  Molecular characterization of acute myeloid leukemia , 2008, Haematologica.

[41]  S. Balcerzak,et al.  A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. , 1995, Leukemia.

[42]  S. Fröhling,et al.  Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.

[43]  M. O’connell,et al.  Escalating the intensity of postremission therapy improves the outcome in acute myeloid leukemia: The ECOG experience , 1992 .

[44]  T. Naoe,et al.  Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission , 2005, Cancer.

[45]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[46]  P. Sonneveld,et al.  Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch–Belgian Haemato‐Oncology Co‐operative Group (HOVON) and Swiss Group for Clinical Cancer Research , 2005, British journal of haematology.

[47]  A. Delannoy,et al.  Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission. , 1991, Bone marrow transplantation.